Media OutReach
Uni-Bio Science Group Limited Announces 2024 Annual Results
Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share Strengthening Presence in Osteoporosis, Ophthalmology, and Aesthetic Medical Markets
HONG KONG SAR – EQS Newswire – 27 March 2025 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2024 (the “Period”).
Key Accomplishments in 2024
During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:
1. The Group recorded a 14.1% year-on-year (“YoY”) increase in revenue, reaching approximately HK$553.0 million. With its approval in January 2024 and subsequent launch in March 2024, Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations.
2. Profit for the Year soared by16.8% YoY to approximately HK$82.8 million, marking a historic high. These results reaffirm the Group’s solid market position and its ability to deliver sustainable, high-quality growth as a leading biopharmaceutical company.
3. The board of directors (“Board”) has declared a dividend payment for 2024 of HK$0.277 cents per share, marking the historic first for the Company. This is particularly encouraging, as it represents an important milestone for a research-oriented biopharmaceutical company. The Board is also pleased to announce the approval and adoption of a dividend payout policy of no less than 20% of its net profit for the current year.
4. In January 2024, the China National Medical Products Administration (“NMPA”) officially approved the launch of Bogutai®, marking a major breakthrough for the Group in osteoporosis and orthopedic disease management. Since its market debut in early 2024, Bogutai® has gained remarkable traction, achieving a patient retention rate exceeding 70%.
5. In December 2024, the Group successful launch its self-developed medical aesthetics product, 肌顏態®. The recombinant collagen dressing, developed in collaboration with Chongqing Minji Medical Device Co., Ltd., received Class II medical device approval, reinforcing the Group’s commitment to innovative skin repair solutions.
6. In January 2024, the NMPA officially accepted the marketing application for Diquafosol Sodium eye drops, marking a key milestone in the Group’s ophthalmology drug pipeline. During the Year, the Group has already submitted additional data to the Center for Drug Evaluation (CDE). Diquafosol Sodium is expected to receive the marketing approval in the first half of 2025.
7. During the Year, the Group completed the pharmaceutical research and pre-Bioequivalence studies of Esaconazole sulfoate capsules. The formal Bioequivalence trials has been initiated in 2025 to accelerate the launch process.
8. In May 2024, the Group cooperated with Great Bay Bio (GBB) and Pebble Accelerator, a subsidiary of Tigermed to joint development of innovative weight reduction drugs, aiming to revolutionize the treatment of obesity. Through this collaboration, we seek to establish a comprehensive ecological industry chain, spanning from target discovery to antibody generation, druggability verification, process development, clinical pipeline, and ultimately, commercialization.
Annual Results
In 2024, the Group recorded a revenue of approximately HK$553.0 million, representing an increase of 14.1% YoY. The increase in revenue was mainly attributable to the favorable sales performance of the Group’s newly launched product Bogutai®. The Group’s newly launched product Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations. Pinup® recorded a decrease of 2.9% in revenue from approximately HK$247.4 million to approximately HK$240.3 million for the Year. During the Year, the Group was re-selected for the centralized procurement, with a validity period of two years. However, the Group adopted a more selective approach to supplying hospitals in response to certain local policy adjustments. During the Year, revenue generated from GeneTime® was approximately HK$197.9 million, representing an increase of 6.7% YoY. The increase was attributed to the expansion of the Group’s hospital network and additional sales channels beyond hospitals, such as pharmacies and e-commerce platforms. GeneSoft® recorded an increase in revenue from approximately HK$41.3 million to approximately HK$42.5 million, representing an increase of 2.9% YoY. Revenue from Boshutai® declined from approximately HK$10.4 million to approximately HK$9.4 million, representing a decrease of 10.2%. During the Year, Boshutai® was successfully included in the centralized procurement by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years, which secured the Group with new in-hospital orders.
Prospects
Recent advancements in biotechnology, coupled with strong government support, position China’s pharmaceutical landscape for substantial growth, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, according to the IMARC Group. This expansion is driven by technological innovations and a growing elderly population increasingly susceptible to chronic conditions such as diabetes, which boosts pharmaceutical demand. Concurrently, the aesthetic medical sector is emerging as a significant market force, with forecasts indicating a CAGR of 10% to 15% from 2024 to 2027, primarily fueled by rising beauty standards and increased spending among individuals with moderate to high incomes. With the two industries being the Group’s core R&D focuses going forward, it showcases a great potential for the Group to rapidly grow and capture the market shares.
Mr. Kingsley Leung, Chairman of Uni-Bio Science commented, “I am proud to announce that we have reached significant milestones this year, both financially and operationally. As our efforts begin to bear fruit, I am deeply grateful for the unwavering, long-term support of our shareholders. In recognition of this, I am delighted to share two landmark decisions: the declaration of our inaugural dividend and the establishment of a forward-looking dividend payout policy of no less than 20% of its net profit for the current year. These actions reaffirm our steadfast commitment to delivering on our objectives while creating and sustaining value for our shareholders.
Looking forward, we remain steadfast in our commitment to innovation and seizing opportunities within both the pharmaceutical and aesthetic medical sectors. Our vision has consistently focused on diversifying our product offerings while leveraging our strengths in endocrinology, ophthalmology, and dermatology. We are delighted to announce the successful launch of Bogutai® Following this milestone, we will continue to develop best-in-class products, including a PTH microneedle formulation that is less invasive and offers higher bioavailability, as well as a novel antibody drug for weight loss. Significant advancements have also been made in our series of EGF products. Preparations for pilot plant testing of the EGF hydrogel are underway, and Diquafosol Sodium Eye Drop slated for launch in the second quarter of 2025. Additionally, The formal Bioequivalence trials for Esaconazole sulfoate capsules has been initiated in 2025 to accelerate the launch process.
In the aesthetic medical segment, we are excited about the launch of肌顏態® in late December 2024. Building on this momentum, we will accelerate the introduction of other new product lines in 2025 based on Skbrella™ FN. Additionally, we plan to introduce collagen and beauty peptides as advanced skincare raw materials this year. By leveraging our expertise in GeneTime® and 肌顏態®, we aim to create a comprehensive skincare solution for emergency skin repair and stabilization. To foster our product innovation, we are utilizing two new key technology platforms: advanced synthetic biology platform and hydrogel technology. These platforms are expected to drive our product expansion.
To enhance our reach and support product launches, we are expanding our sales channels beyond traditional public and private hospital networks to include pharmacies, online platforms, and aesthetic medical institutions. We are also exploring international markets to bolster our global presence. By adopting a diversified distribution strategy, the Group aims to secure future sales growth while reducing its dependence on regional markets and traditional channels. In support of our company’s growth, the infrastructure for our new factory in Dongguan was fully completed in 2024, marking a significant milestone in our expansion plans. A state-of-the-art BFS packaging line has also been featured, which we believe will enable the Group to command a premium in the market. With these strategic focuses and our commitment to rapid advancement, the Group is well-positioned to solidify its leadership in these dynamic industries and achieve lasting success in the years ahead.”
Hashtag: #Uni-BioScience
The issuer is solely responsible for the content of this announcement.
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.
Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.
For further information, please contact: [email protected]
Air Corporate data reveals 9 in 10 founders incorporated in Hong Kong do so remotely, driven by a 20% surge in Middle Eastern entrepreneurs seeking cost-effective operational alternatives to Dubai.
HONG KONG SAR – Media OutReach Newswire – 15 May 2026 – Air Corporate registered a 40.5% increase in Hong Kong incorporations in 2025, with the first quarter of 2026 already up 48% year-over-year. This data indicates that Hong Kong is reasserting itself as the leading Asian jurisdiction for company formation, fueled by a new wave of remote founders from the Middle East, North Africa, and Europe.
The prevailing narrative over the past five years suggested that Singapore was eclipsing Hong Kong; however, recent incorporation volumes challenge this. According to city-wide official figures cited by Vivian, Founder of Air Corporate, approximately 195,000 companies were registered in Hong Kong in 2025, compared to around 77,000 in Singapore.
“There was a lot of fuss about Singapore taking over Hong Kong as preferred jurisdiction over the last few years, but for 2025 alone, around 195,000 companies were formed in HK, vs around 77,000 for Singapore,” said Vivian. While city-wide registrations rose roughly 35% in 2025, incorporations at Air Corporate specifically grew by 40.5%. Vivian added, “With a 35% increase in the number of companies registered in 2025, Hong Kong is definitely back in the game as the top jurisdiction to start a company.”
The reality of Hong Kong company formation is increasingly global, lean, and founder-led. Nine in ten founders incorporated in Hong Kong with Air Corporate do not live there.
Key demographic and operational insights from Air Corporate’s client base include:
- Approximately 90% of founders operate remotely from abroad, while 10% or less are based in Hong Kong.
- Entrepreneurs aged 35 to 44 represent the largest age cohort at 38%, demonstrating that Hong Kong attracts founders in their prime career years rather than just younger digital nomads.
- Serial entrepreneurs make up 60% of Air Corporate’s client mix, utilizing Hong Kong as an operational base for multiple companies, while first-time founders account for the remaining 40%.
- A total of 89% of new companies are launched by solo founders (58%) or small teams of two to five individuals (31%).
- Mainland China, Hong Kong, Turkey, India, the UAE, Australia, France, and Morocco rank among the top source markets for these founders.
Furthermore, 73% of new Hong Kong incorporations are directly tied to physical goods trade with China. This consists of e-commerce and dropshipping businesses (38%) and the trading of goods (35%). The recovery of in-person trade flows, including events, such as the Canton Fair and various industrial fairs, is pulling foreign founders back into the Greater China orbit and establishing Hong Kong as the natural entry point and financial layer over the world’s largest manufacturing base.
Air Corporate’s data recorded a 20% year-over-year growth in founders originating from the Middle East. This shift highlights a reverse migration where founders previously incorporated in Dubai are now choosing Hong Kong. Based on Vivian’s observations, founders often arrive in Dubai expecting fast incorporation and low costs, but discover that incorporation and maintenance are significantly more expensive than in Hong Kong, and banking remains difficult. Consequently, many founders move to Hong Kong after 12 to 24 months in the UAE, a trend accelerated by the Hong Kong government’s strategic outreach to the region.
For lean, remote-first businesses, speed-to-market is a critical factor. A founder located anywhere in the world can incorporate in Hong Kong and open a working bank account in approximately 7 days using digital banking partners. Currently, 90% of Air Corporate’s clients utilize these digital banking partners.
“Hong Kong and Singapore are the only places in Asia where you can set up your company, get a corporate account, and be in business in less than a week,” concluded Vivian.
Air Corporate is a service provider facilitating company formation and incorporation in Hong Kong for serial entrepreneurs, first-time founders, and remote-first business owners operating globally.
Media Inquiries
To learn more about Hong Kong company formation, visit Air Corporate’s website or contact their team directly.
Hashtag: #AirCorporate
The issuer is solely responsible for the content of this announcement.
Media OutReach
Natural Diamonds Sparkle on The Red Carpet at The 2026 Met Gala Celebrating “Costume Art”
Today’s biggest stars express individuality and confidence with natural diamonds
NEW YORK, US – Media OutReach Newswire – 15 May 2026 – The 2026 Met Gala celebrating “Costume Art” took place May 4th at the Metropolitan Museum of Art in New York City, bringing together leading figures from across the globe for an unforgettable evening. These tastemakers showcased the most classic, refined and distinctive diamond jewelry looks of the season. Below, A Diamond is Forever highlights the standout trends from the event.
Desert diamonds
Desert diamonds emerged as a striking throughline on the Met Gala carpet, with a range of hues in distinctive settings taking focus.
Rihanna led the trend in a pair of exceptionally rare old Moghul Golconda fancy brown-yellow diamond earrings by Glenn Spiro, featuring two pear-shaped natural diamonds totaling 51.9 carats. Doja Cat offset her all nude look with a pair of large Leviev Diamonds floral-shaped earrings while Paloma Elsesser made a statement in a 29.5-carat diamond necklace by Bernard James, centered around a 15-carat fancy light yellow pear-shaped natural diamond. Cara Delevingne wore a De Beers London Forces of Nature High Jewelry ring, featuring marquise yellow diamonds set as eyes, while Emma Chamberlain opted for yellow and white diamond earrings by Chopard, underscoring the continued allure of warm diamond hues.
Magnificent Diamond Earrings
A wide variety of captivating silhouettes defined the natural diamond earrings on the Met Gala carpet. Zoë Kravitz delivered a modern twist with oversized diamond flower earrings by Jessica McCormack. Chase Sui Wonders opted for Jean Schlumberger by Tiffany & Co. Sea Fan earrings, bringing an element of sculptural artistry to the look. Gracie Abrams selected gently dangling Chanel earrings, adding understated fluidity, while Connor Storrie selected simple hoop earrings from Tiffany & Co., reinforcing the clean and enduring appeal of natural diamonds.
Standout Diamond Moments
Natural diamonds appeared in personal, unconventional and eye-catching ways, offering moments of surprise and awe. Power couple Beyoncé and Jay-Z embodied this trend with Beyoncé wearing Chopard’s Queen of Kalahari necklace, named after the rare 342-carat diamond that provided 23 stones for Chopard’s Garden of Kalahari collection. Jay-Z contributed to the narrative with a vintage diamond brooch by Briony Raymond worn at the collar as an unexpected placement that underscored the piece’s versatility. Isha Ambani made the styling of diamonds an art form in itself, wearing her own diamond jewelry featuring approximately 150 carats of old mine-cut diamonds, including a three-strand necklace and chandelier earrings, while also incorporating diamonds sewn directly into the bodice of her sari to represent significant moments in her life.
Together, these looks highlighted a shift toward natural diamonds as vessels of personal expression, styled with intention, individuality, and a sense of the unexpected.
Hashtag: #MetGala #RedCarpet #ADiamondisForever #NaturalDiamonds #Diamonds
https://adiamondisforever.com/
https://www.linkedin.com/company/debeersgroup/
http://www.twitter.com/DeBeersGroup
https://www.facebook.com/profile.php?id=61571905725935
https://www.instagram.com/adiamondisforeverhk/
The issuer is solely responsible for the content of this announcement.
Media OutReach
Turn Your Savings into a Front-Row Experience: HL Bank Singapore Offers Exclusive Passes to AsiaTop Music Festival 2026
The premier music festival will play host to 16 K-pop, regional and Malaysian stars including, in performance order: Day 1 – NexT1DE, Aina Abdul, Belle Sisoski, Win Metawin, NMIXX, WINNER, DAESUNG, KUN. Day 2 – Uriah See, Firdhaus, Butterbear, 82MAJOR, STAYC, CRAVITY, TWS, CxM
SINGAPORE – Media OutReach Newswire – 14 May 2026 – Your next major K-pop experience is just a savings goal away as HL Bank Singapore (“HLB Singapore”) bridges the gap between financial wellness and the front row. In an exclusive collaboration designed for the ultimate music enthusiast, the bank is offering fans the chance to secure a pair of sought-after AsiaTop Music Festival 2026 tickets, valued at up to RM1,098 (approx. S$355), simply by growing their wealth.
This unique initiative stems from the regional synergy between Hong Leong Bank (“HLB”) and Tencent Music Entertainment Group (JOOX and QQ Music). By aligning with Visit Malaysia Year and Visit Selangor Year 2026, HLB is transforming the traditional banking experience into a gateway for premium entertainment. Scheduled for 30 and 31 May 2026 at the iconic Sepang International Circuit, the festival promises a high-octane weekend featuring an elite lineup of Asian superstars, including the largest K-pop showcase in the ASEAN region.
Securing a spot at the heart of the action has been streamlined through the iSavings Reward Campaign, running from 9 May 2026 to 18 May 2026. To participate, fans first decide on their preferred festival experience, selecting either a pair of Standard Passes with a S$5,000 deposit or the high-energy, nearer-to-the-stars Rockzone Passes with a S$8,282 deposit for their chosen day.
Once a tier is selected, customers can register by depositing the qualifying funds into an iSavings account via FAST or Links transfer. To validate their entry, customers must include the specific Comment Code, such as PALLIR1 for Day 1 Rockzone, within the funds transfer description. The qualifying balance must be maintained within the account for a six-month (182 days) earmarked period.
With only 88 pairs of tickets available for this exclusive campaign, the stakes are high. Allocation is limited to 22 pairs per day for each ticket category and will be awarded strictly on a first-come, first-served basis. Fans are encouraged to act quickly to ensure their savings work as hard as they do while securing a premier seat at the musical event of the year.
For full terms & conditions, and further details, please visit: www.hlbank.com.sg/AsiaTop2026
Hashtag: #HLBankSingapore
The issuer is solely responsible for the content of this announcement.
HL Bank Singapore
HL Bank Singapore is the Singapore branch of Hong Leong Bank Berhad, a leading digital-centric Malaysia-based financial services institution with a rooted heritage in the country spanning over 120 years. Operating under a Full Bank Licence in Singapore, HL Bank offers a comprehensive range of financial services to our business, retail and high networth customers through our 4 core business segments – Business & Corporate Banking, Personal Financial Services, Private Wealth Management and Global Markets.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn